Discovery of the nonfunctional CYP2D6 31 allele in Spanish, Puerto Rican, and US Hispanic populations.
BACKGROUND
CYP2D6 31 (4042G>A, R(440)H) is an allelic variant of the highly polymorphic cytochrome P450 2D6 enzyme that has been associated with reduced functional activity. The US Food and Drug Administration (FDA)-cleared AmpliChip CYP450 test detects the 4042G>A single nucleotide polymorphism (SNP) but an allele assignment could not be made in two Spanish and two Puerto Rican individuals heterozygous for 4042G>A, resulting in no-calls. We aimed to resolve the CYP2D6 31 no-calls, determine the allele haplotype, and corroborate that CYP2D6 31 is associated with a poor metabolizer phenotype.


METHODS
CYP2D6 genotyping was carried out using the AmpliChip CYP450 test and long-range polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism (RFLP) platforms. Allele haplotype was determined by cloning and sequence analysis. Allele frequencies were determined in five population samples.


RESULTS
A 6.6-kb long-range PCR product comprising the entire CYP2D6 gene and flanking regions was sequenced to determine the CYP2D6 31 haplotype. Identical sequences were obtained from both Puerto Ricans selected for sequence analysis. One Spanish individual with a CYP2D6 4/31 genotype was phenotyped as a poor metabolizer with the CYP2D6 probe drug dextromethorphan (urinary ratio DM/DX=0.71). The frequency of CYP2D6 31 was determined in 176 Spanish (0.57%), 50 Puerto Rican (2.0%), and 150 Hispanic (0.33%) people. CYP2D6 31 was absent in 237 North American Caucasians and 154 African Americans.


CONCLUSIONS
CYP2D6 31 was associated with poor metabolism of dextromethorphan in vivo, which is consistent with a previous report classifying this allelic variant as nonfunctional. The discovery of CYP2D6 31 in Spanish people only (or of Spanish ancestry) suggests that it may contribute to CYP2D6 variability in individuals of Spanish ancestry.
Gaedigk
Andrea
A
Division of Developmental Pharmacology & Experimental Therapeutics, Children's Mercy Hospital and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA. agaedigk@cmh.edu
Isidoro-García
Maria
M
Pearce
Robin E
RE
Sánchez
Santiago
S
García-Solaesa
Virginia
V
Lorenzo-Romo
Carolina
C
Gonzalez-Tejera
Gloria
G
Corey
Susan
S
D000328:Adult; D000368:Aged; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics*; D003915:Dextromethorphan / Q000378:metabolism; D005260:Female; D005787:Gene Frequency; D006239:Haplotypes; D006630:Hispanic or Latino / Q000235:genetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D011647:Puerto Rico / Q000208:ethnology; D013030:Spain / Q000208:ethnology
D003915:Dextromethorphan; D019389:Cytochrome P-450 CYP2D6
Ther Drug Monit. 2006 Oct;28(5):673-7
17038884
Drug Metab Dispos. 2001 Oct;29(10):1263-8
11560868
Anal Bioanal Chem. 2008 Nov;392(6):1093-108
18695978
Pharmacogenet Genomics. 2007 Feb;17(2):93-101
17301689
J Clin Pharmacol. 2008 Sep;48(9):1041-51
18728242
Pharmacogenetics. 1997 Jun;7(3):193-202
9241659
Proteins. 2005 May 1;59(2):339-46
15726636
CNS Spectr. 2009 Jan;14(1):19-34
19169185
Clin Pharmacol Ther. 2007 Apr;81(4):510-6
17301735
Pain Med. 2009 Jul-Aug;10(5):799-805
19523031
Pharmacogenomics J. 2009 Feb;9(1):34-41
18591960
Ther Drug Monit. 2001 Jun;23(3):228-31
11360030
Naunyn Schmiedebergs Arch Pharmacol. 2004 Jan;369(1):23-37
14618296
Clin Pharmacol Ther. 2008 Feb;83(2):234-42
17971818
Clin Pharmacol Ther. 2002 Jul;72(1):76-89
12152006
Am J Hum Genet. 2008 Dec;83(6):725-36
19061982